EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Intravenous perampanel as an alternative to the oral formulations in Japanese patients with epilepsy

Ryosuke Hanaya iD, Yuichi Kubota iD, Masahiro Mizobuchi, Koji Iida, Tomonori Ono iD, Hiromichi Motooka, Naoki Nakano, Ayataka Fujimoto iD, Masaki Iwasaki iD, Masafumi Fukuda, Akihiko Kondo, Katsuhisa Uruno und 5 weitere

Epilepsia Open · 2023-12 · 8 (4) · 1369-1382

DOI: 10.1002/epi4.12804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, online erschienen am 30.08.2023. Verfasst von Ryosuke Hanaya und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Kagoshima University, Graduate School of Medical and Dental Sciences, Kagoshima, Japan. Hauptthemen laut MEDLINE: Anticonvulsants, East Asian People, Epilepsy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eisai Inc., Eisai Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Perampanel is an oral anti‐seizure medication, which is approved in Japan for focal‐onset seizures, with/without focal to bilateral tonic–clonic seizures, as monotherapy/adjunctive therapy in patients aged 4 years and older. Treatment for generalized tonic–clonic seizures as adjunctive therapy in patients aged 12 years and older is approved as well. We evaluated the feasibility of intravenous (IV) administration of perampanel as an alternative to oral administration.

Methods

Study 240 (NCT03754582) was an uncontrolled, open‐label study of IV perampanel, conducted in 21 Japanese patients with epilepsy who received a stable dose of 8–12 mg/day of oral perampanel. Patients received 30‐minute IV infusions at equivalent daily doses of oral perampanel for 4 days, then were switched back to oral perampanel. Safety, tolerability, plasma concentration, and maintenance of efficacy throughout the transition between IV and oral dosing of perampanel were assessed. As supportive data, a subgroup analysis was also conducted using data from healthy Japanese subjects (n = 18) who were enrolled in Study 050 (NCT03376997) investigating the pharmacokinetics and safety of IV perampanel in healthy subjects who received an IV infusion (30‐, 60‐, or 90‐minute) of perampanel 12 mg and a single oral administration of perampanel 12‐mg tablet.

Results

In Study 240, the transition between 30‐minute IV and oral perampanel dosing was associated with a ≤1.4‐fold increase in the mean change in maximum observed concentration of perampanel. Seizure outcomes demonstrated no considerable changes in efficacy before, during, or after 30‐minute IV dosing of perampanel. The safety profiles were similar between IV and oral formulations. In Study 050, the pharmacokinetics of 30‐ or 60‐minute IV infusion of perampanel further support the interchangeability between oral and IV formulations in the Japanese subjects. Significance These results support that 30‐minute IV perampanel may be a potential short‐term alternative to oral formulations for patients with epilepsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEast Asian PeopleEpilepsyHumansTreatment OutcomeAdministration, IntravenousNitrilesPyridones

Stichwörter der Autor:innen

anti-seizure medicationfocal-onset seizuresgeneralized tonic-clonic seizuresperampanelpharmacokinetics

Substanzen

AnticonvulsantsperampanelNitrilesPyridones

Autor:innen und Institutionen

  • Department of Neurosurgery, Kagoshima University, Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
  • Epilepsy Center, TMG Asaka Medical Center, Asaka, Japan.
  • Department of Neurology, Nakamura Memorial Hospital, Sapporo, Japan.
  • Epilepsy Center, Hiroshima University Hospital, Hiroshima, Japan.
  • Epilepsy Center, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
  • Department of Neuropsychiatry, Kurume University, Kurume, Japan.

ORCID-Profile: Ryosuke Hanaya, Yuichi Kubota, Tomonori Ono, Ayataka Fujimoto, Masaki Iwasaki

Förderung

  • Eisai Inc.
  • Eisai Canada

Zitieren

APA

Hanaya, R., Kubota, Y., Mizobuchi, M., Iida, K., Ono, T., Motooka, H., Nakano, N., Fujimoto, A., Iwasaki, M., Fukuda, M., Kondo, A., Uruno, K., Yamamuro, S., Yamaguchi, K., Onishi, K., Ngo, L. Y., & Inoue, Y. (2023). Intravenous perampanel as an alternative to the oral formulations in Japanese patients with epilepsy. Epilepsia Open, 8(4), 1369-1382. https://doi.org/10.1002/epi4.12804

Vancouver

Hanaya R, Kubota Y, Mizobuchi M, Iida K, Ono T, Motooka H, et al. Intravenous perampanel as an alternative to the oral formulations in Japanese patients with epilepsy. Epilepsia Open. 2023;8(4):1369-1382. doi:10.1002/epi4.12804

BibTeX
@article{Hanaya2023,
  author = {Hanaya, Ryosuke and Kubota, Yuichi and Mizobuchi, Masahiro and Iida, Koji and Ono, Tomonori and Motooka, Hiromichi and Nakano, Naoki and Fujimoto, Ayataka and Iwasaki, Masaki and Fukuda, Masafumi and Kondo, Akihiko and Uruno, Katsuhisa and Yamamuro, Shintaro and Yamaguchi, Kohei and Onishi, Kisaki and Ngo, Leock Y and Inoue, Yushi},
  title = {Intravenous perampanel as an alternative to the oral formulations in Japanese patients with epilepsy},
  journal = {Epilepsia Open},
  year = {2023},
  volume = {8},
  number = {4},
  pages = {1369--1382},
  doi = {10.1002/epi4.12804}
}
Kostenlos starten →